ANYL 163 |
| Novel peptide-coated drug-loaded Dynamic Nano-Platforms (DNPs) have been developed and tested as potential radio-/photo-sensitizers for the purpose of increasing the efficiency of radiotherapy (RT)/photodynamic therapy (PDT). Fluorescein isothiocyanate (FITC) was labeled on the surface of amine functionalized poly acrylamide (AFPAA) nanoparticles (NPs), which have been prepared via microemulsion process. The resulting NPs were then conjugated with a particular peptide, which can specifically target MDA-435 human breast cancer cells. The results of intracellular accumulation of peptide-coated DNPs indicated that our peptide-coated DNPs can go selectively into cancer cells and have the remarkable property of being able to deliver a therapeutic agent into the tumor cells. Mitomycin C (MMC) is a bioreductive antitumor agent that can be activated by ionizing radiation to cytotoxic species that kill the cancer cells. In vitro studies showed that peptide-targeted MMC-modified DNPs are more efficient in terms of cell killing by ionizing radiation since targeted MMC-DNPs can go into the cancer cells while untargeted MMC-DNPs only stay outside the cells. It can be expected that targeted MMC-DNPs will work much better than free MMC in vivo therapy since free MMC will go into every cell, cancerous or healthy, while targeted MMC-DNPs will go only into tumor cells. This will also enable us to develop peptide-targeted DNPs containing photosensitizers to enhance PDT efficiency. |
|
General Papers
7:00 PM-9:00 PM, Sunday, 28 August 2005 Washington DC Convention Center -- Hall A, Poster
Sci-Mix
Division of Analytical Chemistry |